drugset
drugset / Trial / NCT03128606

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects.

NCT03128606 ↗

Phase 1 Completed 81 enrolled Lakefront Biotherapeutics NV
RandomizedSequentialQuadruple-blindBasic science

Summary

The study is a First-in-Human, Phase I, randomized, double-blind, placebo-controlled, single center study, evaluating single and multiple ascending oral doses of GLPG3067 and the combination of GLPG3067 and GLPG2222 and the combination of GLPG3067,GLPG2222 and GLPG2737 given for 14 days in healthy women of non-childbearing potential. The purpose of the study is to evaluate the safety and tolerability of single ascending oral doses and multiple ascending oral doses of GLPG3067 given to healthy women of non-childbearing potential compared to placebo, as well as of multiple oral doses of the combination of GLPG3067/GLPG2222 compared to matching placebo for each compound and multiple oral doses of the combination of GLPG3067/GLPG2222/GLPG2737 compared to matching placebo for each compound.

Timeline

Start
2017-03-28
Primary completion
2018-02-20
Completion
2018-02-20

Drugs

EvaluationDrugModalityDoseRoute
Subject GLPG2737 Small molecule — Oral
Subject Galicaftor Small molecule — Oral
Subject Navocaftor Small molecule — Oral

Indications

No indication recorded.